Key facts
- Raziel Therapeutics’s last known valuation is $34.0M (Dec 2019).
- It has raised $29.3M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Innovation Authority, Peregrine Ventures, Wille Finance, Avi Meisler, Catalyst Investments — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Raziel Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Raziel Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Raziel Therapeutics
Manufacturer of injectable drugs designed to decrease submental fat and fat disorders. The company offers a single injection treatment into subcutaneous fat that causes immediate fat cell death at the injection site, enabling healthcare professionals to provide patients with a significant treatment fat reduction for long periods without any invasive procedures.
- Sector
- Healthcare
- HQ
- Rehovot, Israel
- Founded
- 2012
- Employees
- 7
- Website
- raziel-therapy.com/
- Ownership
- Privately Held (backing)
Raziel Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Raziel Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Raziel Therapeutics in its N-PORT filings yet. We sweep new filings monthly.